Impact of Ribociclib on Head and Neck Squamous Cell Cancer

NCT03179956 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Ribociclib

Sponsor

Fox Chase Cancer Center